达格列净对不同左心室射血分数心衰患者疗效及预后研究  

Study on the efficacy and prognosis of dapagliflozin in patients with heart failure with different left ventricular ejection fractions

作　　者：谢倩倩 徐飞[1] 周勇[1] Xie Qianqian;Xu Fei;Zhou Yong(Department of Cardiology,Suzhou Hospital Affiliated to Anhui Medical University,Suzhou 234000,Anhui,China)

机构地区：[1]安徽医科大学附属宿州医院心内科,安徽宿州234000

出　　处：《现代科学仪器》2024年第5期171-175,共5页Modern Scientific Instruments

摘　　要：目的:分析达格列净对不同左心室射血分数心衰患者疗效及预后影响。方法:选取2022年10月至2023年11月收入的200例不同左心室射血分数心衰患者,根据左心室射血分数将其分为>40%组和≤40%组。两组患者在常规治疗基础上均使用达格列净。3个月后评估肾功能、BNP水平等指标,并随访6个月。结果:两组在达格列净治疗后,肾功能、BNP水平、心脏结构参数、BMI、6分钟步行距离、静息心率以及各类并发症发生率等均有显著改善(P<0.05)。且两组治疗后各项指标相近(P>0.05)。结论:达格列净在治疗各种左心室射血分数的心衰患者时均表现良好,且疗效和预后不受射血分数影响。Objective:To analyze the efficacy and prognostic impact of dapagliflozin on heart failure patients with different left ventricular ejection fractions.Method:200 heart failure patients with varying left ventricular ejection fractions,admitted between October 2022 to November 2023,were selected and categorized into two groups based on their ejection fractions:>40%and≤40%.Both groups received dapagliflozin alongside conventional treatment.Various parameters,including renal function and BNP levels,were assessed after 3 months,followed by a 6-month follow-up.Results:Significant improvements were observed in renal function,BNP levels,cardiac structural parameters,BMI,6-minute walk distance,resting heart rate,and the incidence of various complications in both groups after dapagliflozin treatment(P<0.05).The post-treatment indicators were similar between the two groups(P>0.05).Conclusion:Dapagliflozin demonstrates effective treatment for heart failure patients across various left ventricular ejection fractions,with its efficacy and prognosis unaffected by the ejection fraction.

关 键 词：达格列净 左心室射血分数 心力衰竭 

分 类 号：R246.1[医药卫生—针灸推拿学]